Related Experiment Video

Updated: Mar 2, 2026

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

8.4K

Novel nanoparticle delivery systems for rifampicin: an effective strategy against tuberculosis?

Jiří Trousil1, Martin Hrubý1

  • 1Institute of Macromolecular Chemistry of the Academy of Sciences of the Czech Republic, Heyrovsky sq. 2, Prague 6, 162 06, Czech Republic.

Nanomedicine (London, England)
|May 20, 2017
PubMed
Abstract

No abstract available in PubMed .

Keywords:
nanoparticlesrifampicintuberculosis

More Related Videos

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

9.2K
An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.3K

Related Experiment Videos

Last Updated: Mar 2, 2026

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

8.4K
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

9.2K
An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.3K

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

691
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
691
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

7.1K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
7.1K

Articles linked to this work by shared authors, journal, and citation graph.

Correction: Catalytic degradation of N-acyl-homoserine lactone using a copper complex of a TACN derivative: implications for quorum sensing interference.

Dalton transactions (Cambridge, England : 2003)·2026

Targeted delivery of berberine via ROS-sensitive polymersomes enhances its hepatoprotective activity in CCl4-intoxicated mice.

Nanoscale advances·2025

Synthesis of morphologically diverse dual thermo- and pH-responsive nano-objects via RAFT-mediated emulsion PISA.

Nanoscale advances·2025

May the target be with you: polysaccharide-coated upconverting nanoparticles for macrophage targeting.

Nanoscale·2025

Catalytic degradation of N-acyl-homoserine lactone using a copper complex of a TACN derivative: implications for quorum sensing interference.

Dalton transactions (Cambridge, England : 2003)·2025

Novel antitubercular agents based on 2,4-disubstituted 5-(aryl-2-ylmethyl)-5H-pyrrolo[3,2-d]pyrimidines.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2025

Astragaloside IV and rapamycin co-loaded bone marrow mesenchymal stem cell-derived exosome nanocarriers for targeted modulation of the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.

Nanomedicine (London, England)·2026

Glutathione-responsive gambogic acid-conjugated carboxymethyl chitosan/graphene quantum dot nanoparticles for chemo-photothermal-photodynamic synergistic therapy of drug-resistant breast cancer.

Nanomedicine (London, England)·2026

Nanoparticles for fluorescence-guided breast cancer surgery: advances in in vivo preclinical research.

Nanomedicine (London, England)·2026

Cationic lipid-based targeted nanocarriers for respiratory diseases in children: prospects and challenges.

Nanomedicine (London, England)·2026

LPR-1-Mediated targeted intranasal delivery of lentinan-loaded polymeric nanocarriers for GBM therapy via modulation of apoptotic signalling.

Nanomedicine (London, England)·2026

Intradermal immunoengineering with mRNA.

Nanomedicine (London, England)·2026

Design of ZnO-Based Nanomaterials and Nanocomposites for Antibacterial Applications.

ACS applied bio materials·2026

Cranioplasty for a Cranial Bone Defect Associated with Giant Congenital Melanocytic Nevus.

NMC case report journal·2026

ZIF-8 Nanodrug Delivery Systems: Construction Strategies, Functional Modifications, and Advances in Synergistic Tumor Therapy.

International journal of nanomedicine·2026

Inorganic Nanomaterials can Promote or Inhibit Tumor Metastasis Depending on Tumor Microenvironment Composition.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

Nanocellulose-directed ultrasmall copper nanoparticles for durable antimicrobial interfaces.

Nanoscale·2026

Neuroendoscopic single-nostril nasoseptal approach for tuberculum sellae meningiomas: technical description and preliminary clinical experience.

Frontiers in neurology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us